ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data

ArriVent BioPharma (AVBP) reported robust updated Phase 1b FURTHER trial results for firmonertinib in first-line EGFR PACC-positive non-small cell lung cancer, demonstrating a 68.2% confirmed overall response rate at the 240mg dose and a median progression-free survival of 16.0 months. The drug also showed significant efficacy in patients with brain metastases, achieving a 41% complete response rate. H.C. Wainwright reiterated a Buy rating and raised its price target to $40, citing these favorable outcomes compared to existing treatments. ArriVent plans to advance firmonertinib to a global Phase 3 trial, positioning it to potentially address a significant treatment gap in NSCLC.

Analysis

ArriVent BioPharma (AVBP) has presented compelling updated data from its Phase 1b FURTHER trial for firmonertinib in non-small cell lung cancer (NSCLC) with EGFR PACC mutations. The results demonstrate significant efficacy, particularly at the 240mg dose, which achieved a 68.2% confirmed overall response rate (ORR) and a median progression-free survival (mPFS) of 16.0 months. These outcomes compare favorably to historical data for existing tyrosine kinase inhibitors, which reported ORRs between 37.2% and 59.6%. Crucially, the drug showed strong activity in patients with brain metastases, a difficult-to-treat population, with a 41% complete response rate. The safety profile appears manageable, with 22.7% of patients at the 240mg dose experiencing grade 3 or higher treatment-related adverse events. Financially, InvestingPro data indicates a strong position, with a current ratio of 14.34, suggesting the company is well-capitalized to advance firmonertinib into a global Phase 3 trial. This positive clinical and financial picture is reinforced by H.C. Wainwright's reiterated Buy rating and increased price target of $40, substantially above the current trading price. The primary risk highlighted is forthcoming competitive data from Black Diamond Therapeutics (BDTX) and ORIC Pharma.

Key Decisions for Investors

• The robust Phase 1b data, showing a 16.0-month median progression-free survival and high response rates, serves as a significant de-risking event, justifying a bullish stance on ArriVent's lead asset.
• Investors should consider the current valuation, with the stock trading at $22.91 against analyst targets of $37-$45, as a potentially attractive entry point given the company's strong balance sheet to fund the pivotal Phase 3 trial.
• It is critical to monitor upcoming clinical data from competitors, specifically Black Diamond Therapeutics and ORIC Pharma, as positive results from these peers could materially impact firmonertinib's future market share and competitive positioning.